KR20240157138A - 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체 - Google Patents

상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체 Download PDF

Info

Publication number
KR20240157138A
KR20240157138A KR1020247035784A KR20247035784A KR20240157138A KR 20240157138 A KR20240157138 A KR 20240157138A KR 1020247035784 A KR1020247035784 A KR 1020247035784A KR 20247035784 A KR20247035784 A KR 20247035784A KR 20240157138 A KR20240157138 A KR 20240157138A
Authority
KR
South Korea
Prior art keywords
alkyl
group
aryl
methyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247035784A
Other languages
English (en)
Korean (ko)
Inventor
프리드릭 루나 가다슨
프레드릭 레만
피터 테오도로빅
Original Assignee
에피-엔도 파마슈티컬즈 이에이치에프.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55133040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240157138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에피-엔도 파마슈티컬즈 이에이치에프. filed Critical 에피-엔도 파마슈티컬즈 이에이치에프.
Publication of KR20240157138A publication Critical patent/KR20240157138A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
KR1020247035784A 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체 Pending KR20240157138A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1520419.1 2015-11-19
GBGB1520419.1A GB201520419D0 (en) 2015-11-19 2015-11-19 Compounds
KR1020187017001A KR102724114B1 (ko) 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체
PCT/EP2016/078360 WO2017085329A1 (en) 2015-11-19 2016-11-21 Azithromycin derivatives with epithelial barrier enhancement properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017001A Division KR102724114B1 (ko) 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체

Publications (1)

Publication Number Publication Date
KR20240157138A true KR20240157138A (ko) 2024-10-31

Family

ID=55133040

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247035784A Pending KR20240157138A (ko) 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체
KR1020187017001A Active KR102724114B1 (ko) 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187017001A Active KR102724114B1 (ko) 2015-11-19 2016-11-21 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체

Country Status (19)

Country Link
US (3) US10723752B2 (https=)
EP (2) EP3377511B1 (https=)
JP (2) JP6849896B2 (https=)
KR (2) KR20240157138A (https=)
CN (2) CN108290919B (https=)
CA (1) CA3005088A1 (https=)
CY (1) CY1123418T1 (https=)
DK (1) DK3377511T3 (https=)
ES (1) ES2810703T3 (https=)
GB (1) GB201520419D0 (https=)
HR (1) HRP20201246T1 (https=)
HU (1) HUE050307T2 (https=)
LT (1) LT3377511T (https=)
PL (1) PL3377511T3 (https=)
PT (1) PT3377511T (https=)
RS (1) RS60698B1 (https=)
SI (1) SI3377511T1 (https=)
SM (1) SMT202000426T1 (https=)
WO (1) WO2017085329A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds
KR20220156570A (ko) 2020-03-12 2022-11-25 조에티스 서비시즈 엘엘씨 면역조절성 유레아 아잘라이드
AU2022343476B2 (en) * 2021-09-07 2025-02-20 Zoetis Services Llc Immunomodulating azalides
CN121038797A (zh) 2023-03-22 2025-11-28 艾比恩多制药有限责任公司 用于治疗嗜酸性粒细胞相关疾病的阿奇霉素衍生物
GB202404587D0 (en) 2024-03-28 2024-05-15 Epiendo Pharmaceuticals Ehf Chemical forms
GB202412461D0 (en) 2024-08-23 2024-10-09 Epiendo Pharmaceuticals Ehf Medial use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
HRP20010018A2 (en) * 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
RU2330858C2 (ru) 2002-07-08 2008-08-10 Глаксомитклайн Истраживацки Центар Загреб Д.О.О. Новые соединения, составы и способы лечения воспалительных заболеваний и состояний
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
PT1851236E (pt) 2005-01-13 2010-10-25 Glaxosmithkline Zagreb Macrólidos com actividade anti-inflamatória
EP1841776B1 (en) * 2005-01-13 2008-12-31 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Decladinosyl-macrolides with anti-inflammatory activity
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
RU2455308C2 (ru) 2006-05-01 2012-07-10 Тайсо Фармасьютикал Ко., Лтд. Макролидные производные
CN101074251B (zh) * 2007-06-22 2011-06-15 山东大学 阿奇霉素4＂-氨甲酸酯衍生物、制备方法及其药物组合物
WO2009006403A2 (en) * 2007-06-29 2009-01-08 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof
WO2010086351A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 3'-n-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity
CA2814333A1 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
GB201105633D0 (en) * 2011-04-01 2011-05-18 Norbrook Lab Ltd Antibotic compounds
EP2831083A4 (en) * 2012-03-27 2016-03-09 Michael W Burnet INFLAMMATORY MAKROLIDE
AU2014252462A1 (en) 2013-04-10 2015-10-01 Probiotic Pharmaceuticals Aps Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds

Also Published As

Publication number Publication date
HRP20201246T1 (hr) 2020-11-13
US20220106349A1 (en) 2022-04-07
WO2017085329A1 (en) 2017-05-26
HUE050307T2 (hu) 2020-11-30
CN108290919B (zh) 2022-06-17
SI3377511T1 (sl) 2020-10-30
US20200317710A1 (en) 2020-10-08
CN108290919A (zh) 2018-07-17
PL3377511T3 (pl) 2020-11-16
US12049477B2 (en) 2024-07-30
CY1123418T1 (el) 2021-12-31
CN114933620B (zh) 2026-03-31
EP3708573A1 (en) 2020-09-16
JP2018534324A (ja) 2018-11-22
US20180354981A1 (en) 2018-12-13
LT3377511T (lt) 2020-09-25
US10723752B2 (en) 2020-07-28
JP6849896B2 (ja) 2021-03-31
EP3377511A1 (en) 2018-09-26
RS60698B1 (sr) 2020-09-30
JP2021073303A (ja) 2021-05-13
KR102724114B1 (ko) 2024-10-29
HK1255270A1 (en) 2019-08-09
JP7256558B2 (ja) 2023-04-12
US11236120B2 (en) 2022-02-01
DK3377511T3 (da) 2020-08-17
ES2810703T3 (es) 2021-03-09
CA3005088A1 (en) 2017-05-26
PT3377511T (pt) 2020-08-21
EP3377511B1 (en) 2020-05-13
GB201520419D0 (en) 2016-01-06
CN114933620A (zh) 2022-08-23
KR20180077282A (ko) 2018-07-06
SMT202000426T1 (it) 2020-09-10

Similar Documents

Publication Publication Date Title
KR102724114B1 (ko) 상피성 장벽 향상 특성을 갖는 아지트로마이신 유도체
KR102825246B1 (ko) 테르페닐 화합물의 신규 염
JP5805389B2 (ja) 非経口用抗菌剤
CA2676061A1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
CN116496318A (zh) 一种杂环衍生物及其组合物和药学上的应用
KR20110099791A (ko) 항염증 마크롤리드
JP2018529696A (ja) ヒドロキシアルキルチアジアゾール誘導体
CN101117336A (zh) 7-(4-肟基-3-氨基-1-哌啶基)喹啉羧酸衍生物及其制备方法
US20160031925A1 (en) Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
JP2026512285A (ja) 好酸球関連疾患の治療における使用のためのアジスロマイシン誘導体
HK40037271A (en) Azithromycin derivatives with epithelial barrier enhancement properties
HK1255270B (en) Azithromycin derivatives with epithelial barrier enhancement properties
WO2021138847A1 (en) Macrolide compound and its use of treatment chronic respiratory disease
AU2012244278C1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
CN105492422A (zh) 新型吡咯衍生物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000